<p>, /PRNewswire/ -- CenExel Clinical Research（&#34;CenExel&#34;或&#34;公司&#34;），一家领先的全资临床研究机构网络，今天宣布任命 Dr. Sy Pretorius 为首席执行官，任命自 2026 年 5 月 1 日起生效。Dr. Pretorius 接替 Ryan Brooks，后者将继续担任公司董事会成员。</p>
<p>Dr. Pretorius 将专注于发展 CenExel 的战略合作伙伴关系，提升其治疗领域能力，扩展公司在新市场的足迹，并进一步巩固公司的&#34;卓越中心&#34;运营声誉，以将 CenExel 定位为首屈一指的临床试验机构网络。</p>
<p>&#34;Sy 是一位经验丰富的高管，拥有领导大型制药组织的成功记录，&#34;BayPine LP 合伙人兼公司董事会主席 Tom O'Rourke 表示。&#34;随着 CenExel 进入下一个增长阶段，Sy 独特的管理和科学专业知识的结合将使公司能够显著提升其对制药赞助商、患者和员工的价值主张。在 Ryan 的领导下，CenExel 加强了其运营基础，提升了其差异化的治疗能力，我们感谢他所做的诸多贡献。&#34;</p>
<p>Dr. Pretorius 在临床研究领导方面拥有超过三十年的经验，担任过高级执行和管理职位，在推动全球临床开发项目、早期研究和综合临床试验服务方面发挥了重要作用。他作为医生的背景和培训使他能够从科学战略和运营执行的角度来审视药物开发，始终以患者为中心。</p>
<p>&#34;在临床研究如此激动人心的时刻加入 CenExel，我感到非常荣幸，&#34;Dr. Pretorius 表示。&#34;CenExel 在科学严谨性和运营卓越方面建立了强大的声誉，公司对以患者为中心的研究和护理的承诺令人钦佩和振奋。我期待与我们网络中才华横溢的团队紧密合作，继续推动 CenExel 的发展势头。&#34;</p>
<p>Dr. Pretorius 目前担任 Ergomed Group 的首席执行官，领导 PrimeVigilance、Ergomed CRO 和 ADAMAS 业务的价值创造工作，此前该集团从公开市场转向私募股权所有。在加入 Ergomed 之前，他曾担任 EVERSANA 的首席运营官，负责药物和设备的商业化服务。更早之前，作为 PAREXEL 的临床开发总裁和首席医学官，他监督了 36 亿美元的全球盈亏，并领导了超过 16,000 名员工。</p>
<p>&#34;能够领导 CenExel 并与如此敬业和才华横溢的团队合作，是一种无上的荣幸，&#34;Brooks 先生表示。&#34;我为我们建立的站点网络感到自豪，我们的整个团队专注于推动临床研究并改善新疗法的获取。Sy 是一位备受尊敬的高管，在我们的行业中拥有深厚的经验，我相信他的领导将帮助 CenExel 达到新的高度。&#34;</p>
<p>媒体联系人：</p>
<p>George Protopapadakis</p>
<p>公共关系</p>
<p>CenExel</p>
<p>[email protected]</p>
<p><strong>关于 CenExel</strong></p>
<p>CenExel 是一家领先的全资临床研究机构网络，致力于支持生命科学行业发现和开发改变生命的疗法。</p>
<p>CenExel 在复杂临床试验的设计和执行中提供无与伦比的研究支持，利用科学专业知识、世界级的首席研究员、先进的患者参与策略、优质数据和综合运营卓越。</p>
<p>CenExel 的卓越中心位于多个主要城市，已精确、准确和快速地进行了数千项研究。公司对质量、患者体验和客户成功的坚定承诺确保了成功的临床开发结果。</p>
<p>CenExel 的专业知识和执行能力帮助制药和生物技术公司深入了解疾病，加速临床开发，以提供创新治疗方案并改善全球患者的结果。欲了解更多信息，请访问 www.cenexelresearch.com</p>
<p>来源：CenExel Clinical Research</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9TEEyODAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNDAyUFJfTkVXU19VU1BSX19fX19MQTI4MDE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9TEEyODAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNDAyUFJfTkVXU19VU1BSX19fX19MQTI4MDE5"/></p>

WCGC

伊克力西斯

医疗业 ETF - Vanguard

<p>CenExel 临床研究公司已任命 Dr. Sy Pretorius 为首席执行官，任职时间自 2026 年 5 月 1 日起生效。他接替 Ryan Brooks，后者将继续担任董事会成员。Pretorius 博士旨在增强战略合作伙伴关系，扩大市场影响力，并提升 CenExel 在临床试验中的声誉。拥有超过 30 年的临床研究经验，他曾担任 Ergomed Group 的首席执行官和 EVERSANA 的首席运营官。Brooks 对 Pretorius 博士的领导能力表示信心，认为他能够推动 CenExel 在行业中的增长</p>

<p>, /PRNewswire/ -- CenExel Clinical Research (&#34;CenExel&#34; or the &#34;Company&#34;), a leading, wholly-owned clinical research site network, today announced the appointment of Dr. Sy Pretorius as Chief Executive Officer, effective May 1st, 2026. Dr. Pretorius succeeds Ryan Brooks, who will remain a member of the Company's Board of Directors.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- CenExel Clinical Research（&#34;CenExel&#34;或&#34;公司&#34;），一家领先的全资临床研究机构网络，今天宣布任命 Dr. Sy Pretorius 为首席执行官，任命自 2026 年 5 月 1 日起生效。Dr. Pretorius 接替 Ryan Brooks，后者将继续担任公司董事会成员。</p>
</div><p>Dr. Pretorius will focus on growing CenExel's strategic partnerships, advancing its therapeutic area capabilities, expanding the Company's footprint to new markets, and further entrenching the Company's &#34;centers of excellence&#34; operational reputation to position CenExel as the premier clinical trial site network.</p>
<div class="lb-trans"><p>Dr. Pretorius 将专注于发展 CenExel 的战略合作伙伴关系，提升其治疗领域能力，扩展公司在新市场的足迹，并进一步巩固公司的&#34;卓越中心&#34;运营声誉，以将 CenExel 定位为首屈一指的临床试验机构网络。</p>
</div><p>&#34;Sy is a seasoned executive with a proven track record leading scaled pharmaceutical organizations,&#34; said Tom O'Rourke, Partner at BayPine LP and Chairman of the Company's Board. &#34;As CenExel embarks on its next chapter of growth, Sy's unique combination of management and scientific expertise will enable the Company to meaningfully enhance its value proposition to pharma sponsors, patients, and employees. CenExel strengthened its operational foundation and sharpened its differentiated therapeutic capabilities under Ryan's leadership, and we thank him for his many contributions.&#34;</p>
<div class="lb-trans"><p>&#34;Sy 是一位经验丰富的高管，拥有领导大型制药组织的成功记录，&#34;BayPine LP 合伙人兼公司董事会主席 Tom O'Rourke 表示。&#34;随着 CenExel 进入下一个增长阶段，Sy 独特的管理和科学专业知识的结合将使公司能够显著提升其对制药赞助商、患者和员工的价值主张。在 Ryan 的领导下，CenExel 加强了其运营基础，提升了其差异化的治疗能力，我们感谢他所做的诸多贡献。&#34;</p>
</div><p>Dr. Pretorius joins CenExel with more than three decades of experience in clinical research leadership, spanning senior executive and management roles where he was instrumental in driving global clinical development programs, early-phase research, and integrated clinical trial services. His background and training as a physician equip him to approach drug development with an eye for both scientific strategy as well as operational execution, underpinned by a patient-first approach.</p>
<div class="lb-trans"><p>Dr. Pretorius 在临床研究领导方面拥有超过三十年的经验，担任过高级执行和管理职位，在推动全球临床开发项目、早期研究和综合临床试验服务方面发挥了重要作用。他作为医生的背景和培训使他能够从科学战略和运营执行的角度来审视药物开发，始终以患者为中心。</p>
</div><p>&#34;It is an honor to join CenExel at such an exciting time for clinical research,&#34; said Dr. Pretorius. &#34;CenExel has established a strong reputation for scientific rigor and operational excellence, and the Company's commitment to patient-centric research and care is admirable and energizing. I look forward to working closely with our talented team across the network to continue building on CenExel's momentum.&#34;</p>
<div class="lb-trans"><p>&#34;在临床研究如此激动人心的时刻加入 CenExel，我感到非常荣幸，&#34;Dr. Pretorius 表示。&#34;CenExel 在科学严谨性和运营卓越方面建立了强大的声誉，公司对以患者为中心的研究和护理的承诺令人钦佩和振奋。我期待与我们网络中才华横溢的团队紧密合作，继续推动 CenExel 的发展势头。&#34;</p>
</div><p>Dr. Pretorius currently serves as CEO of Ergomed Group, where he leads value creation efforts across the PrimeVigilance, Ergomed CRO and ADAMAS businesses after the group transitioned from the public market to private equity ownership. Prior to joining Ergomed, he served as Chief Operating Officer at EVERSANA, where he led drug and device commercialization services. Earlier, as President of Clinical Development and Chief Medical Officer at PAREXEL, he oversaw a $3.6 billion global P&amp;L and led more than 16,000 employees worldwide.</p>
<div class="lb-trans"><p>Dr. Pretorius 目前担任 Ergomed Group 的首席执行官，领导 PrimeVigilance、Ergomed CRO 和 ADAMAS 业务的价值创造工作，此前该集团从公开市场转向私募股权所有。在加入 Ergomed 之前，他曾担任 EVERSANA 的首席运营官，负责药物和设备的商业化服务。更早之前，作为 PAREXEL 的临床开发总裁和首席医学官，他监督了 36 亿美元的全球盈亏，并领导了超过 16,000 名员工。</p>
</div><p>&#34;It has been an incredible privilege to lead CenExel and work alongside such a dedicated and talented team,&#34; said Mr. Brooks. &#34;I'm proud of the site network that we have built, with our entire team focused on advancing clinical research and improving access to new therapies. Sy is a highly respected executive with deep experience in our industry, and I am confident that his leadership will help CenExel to achieve new heights.&#34;</p>
<div class="lb-trans"><p>&#34;能够领导 CenExel 并与如此敬业和才华横溢的团队合作，是一种无上的荣幸，&#34;Brooks 先生表示。&#34;我为我们建立的站点网络感到自豪，我们的整个团队专注于推动临床研究并改善新疗法的获取。Sy 是一位备受尊敬的高管，在我们的行业中拥有深厚的经验，我相信他的领导将帮助 CenExel 达到新的高度。&#34;</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>George Protopapadakis</p>
<div class="lb-trans"><p>George Protopapadakis</p>
</div><p>Public Relations</p>
<div class="lb-trans"><p>公共关系</p>
</div><p>CenExel</p>
<div class="lb-trans"><p>CenExel</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>About CenExel</strong></p>
<div class="lb-trans"><p><strong>关于 CenExel</strong></p>
</div><p>CenExel is a leading, wholly owned clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies.</p>
<div class="lb-trans"><p>CenExel 是一家领先的全资临床研究机构网络，致力于支持生命科学行业发现和开发改变生命的疗法。</p>
</div><p>CenExel provides unparalleled research support in the design and execution of complex clinical trials, leveraging scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence.</p>
<div class="lb-trans"><p>CenExel 在复杂临床试验的设计和执行中提供无与伦比的研究支持，利用科学专业知识、世界级的首席研究员、先进的患者参与策略、优质数据和综合运营卓越。</p>
</div><p>Located across multiple major metro areas, CenExel's Centers of Excellence sites have conducted thousands of studies with precision, accuracy, and speed. The company's unwavering commitment to quality, the patient experience, and client success ensures successful clinical development outcomes.</p>
<div class="lb-trans"><p>CenExel 的卓越中心位于多个主要城市，已精确、准确和快速地进行了数千项研究。公司对质量、患者体验和客户成功的坚定承诺确保了成功的临床开发结果。</p>
</div><p>CenExel's expertise and execution capabilities help pharmaceutical, and biotech companies gain deeper insights into diseases, accelerating clinical development to deliver innovative treatments and improve global patient outcomes. To learn more visit www.cenexelresearch.com</p>
<div class="lb-trans"><p>CenExel 的专业知识和执行能力帮助制药和生物技术公司深入了解疾病，加速临床开发，以提供创新治疗方案并改善全球患者的结果。欲了解更多信息，请访问 www.cenexelresearch.com</p>
</div><p>SOURCE CenExel Clinical Research</p>
<div class="lb-trans"><p>来源：CenExel Clinical Research</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9TEEyODAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNDAyUFJfTkVXU19VU1BSX19fX19MQTI4MDE5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA28019&amp;Transmission_Id=202604071402PR_NEWS_USPR_____LA28019&amp;DateId=20260407"/></p>

CenExel 公司任命 Sy Pretorius 博士担任首席执行官